Pharmacyclics is an AbbVie company focused on developing and commercializing innovative therapies for the treatment of certain cancers and immune-mediated diseases. Pharmacyclics and Janssen Biotech Inc., developed and commercialized IMBRUVICA® (ibrutinib), a first-in-class, oral, once-daily therapy that inhibits a protein called Bruton's tyrosine kinase (BTK).
At Janssen Biotech, Inc. we have an urgent commitment to make a difference for cancer patients and those with autoimmune disease. Comprised of Janssen Oncology and Janssen Immunology, we deliver transformational biologic medicines to market, and have built a rich legacy of innovative firsts.
Pharmacyclics LLC and Janssen Biotech, Inc.
999 East Arques Ave
Sunnyvale, California 94085